Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Pfizer, Inc.
EIR
•Pfizer, Inc.•December 5, 2014

Pfizer, Inc. – FDA EIR, Dec 5, 2014

Record Details

The Food and Drug Administration (FDA) conducted a Bioresearch Monitoring (BIMO) inspection of Pfizer, Inc. (445 Eastern Point Rd, Groton, CT) from December 1 to December 5, 2014. This high-priority inspection was a CDER User Fee New Drug Application (NDA) pre-approval and sponsor monitor data validation, focusing on Pfizer's responsibilities as a sponsor under the Bioresearch Monitoring Compliance Program 7348.810. The inspection specifically reviewed the investigational drug Ibrance (palbociclib, PD 0332991) and its associated clinical study protocol A5481003 (PALOMA-1) for advanced breast cancer. During the inspection, six study sites were reviewed, and a comprehensive range of records was examined, including organizational charts, vendor oversight plans, investigator agreements, financial disclosures, monitoring plans and reports, safety reports, adverse events, protocol deviations, and standard operating procedures (SOPs). The FDA concluded that no significant deficiencies were observed during this inspection, and consequently, no FDA Form 483 was issued. The inspection confirmed the firm was following SOPs for reporting protocol deviations, addressing actions from a previous inspection. The recommended and final classification for this inspection was "No Action Indicated" (NAI), meaning no regulatory actions were required from Pfizer, Inc. based on these findings.

Company
Pfizer, Inc.
Inspection date
December 5, 2014
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Matthew C. Watson
  • Timothy M. Glod (Compliance Officer)
View Company Profile

ID · 5e849775-24a2-4fe8-9c38-38923c347f8a

Other documents for Pfizer, Inc.
  • EIR - 2023-04-19April 19, 2023
  • 483 - 2017-06-28June 28, 2017
  • 483 - 2017-06-07June 7, 2017
  • 483 - 2012-02-24February 24, 2012

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Pfizer, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.